Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6598910 | 0.98 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL1341474 | 0.85 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL28509155 | 0.84 | ALDH1A1 (0.77) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL112310 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL29937119 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL31521994 | 0.81 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL1341491 | 0.80 | NFE2L2 (0.46) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL27462411 | 0.80 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL15624568 | 0.79 | SLC9A1 (0.48) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL1341120 | 0.79 | ALDH1A1 (0.57) | ALDH1A1CYP3A4TDP1TSHRADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724731-B | Two-step preparation method of 4-fluoro-2-methoxy-5-nitroaniline | 山东仁一生物科技有限责任公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118724731-A | Two-step preparation method of 4-fluoro-2-methoxy-5-nitroaniline | 山东仁一生物科技有限责任公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118439975-A | Preparation method of 4-fluoro-2-methoxy-5-nitro-N-tert-butoxyaniline | 川北医学院 | 2024-08-06 | — | — | CN | claimed |
| CN-116199569-A | Preparation method of antitumor drug Lin Zage key phenol intermediate | 浙江科聚生物医药有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-112409192-A | Purification method of 4-fluoro-2-methoxyaniline | 启东东岳药业有限公司 | 2021-02-26 | — | — | CN | claimed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720060-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2026-04-08 | — | — | EP | disclosed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | Jiangsu Yahong Meditech Co. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| CN-1076195-A | N-Benzoylbenzene sulfonamide derivatives | GLAXO GROUP LTD (GB) | 1993-09-15 | — | — | CN | disclosed |
| CN-1073430-A | Benzanilide derivatives | GLAXO GROUP LTD (GB) | 1993-06-23 | — | — | CN | disclosed |
| CN-1071919-A | N-Benzoylbenzene sulfonamide derivatives | GLAXO GROUP LTD (GB) | 1993-05-12 | — | — | CN | disclosed |
| WO-1993006084-A1 | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |
| EP-0533267-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0533268-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0485157-A2 | Esters and amides of substituted pyrrole acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4044049-A | Phenyl benzoic acid compounds | MERCK & CO., INC. (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI1, PADI6 | ALDH1A1 163/4885CYP3A4 273/4885TDP1 8/4885 |
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | NOS1, NQO1, NOS2 | ALDH1A1 752/4885CYP3A4 120/4885TDP1 1968/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | ALDH1A1 2563/4885CYP3A4 4702/4885TDP1 1860/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | ALDH1A1 4237/4885CYP3A4 3166/4885TDP1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.